Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. The company aims to improve women’s health by providing granular and clinically actionable information at the point of care, enabling more informed clinical decisions. Through deep technological breakthroughs, Nanopath is developing novel diagnostic technologies designed to transform the molecular diagnostic paradigm. Its first-in-class molecular diagnostic platform enables scalable, point-of-care disease diagnosis, supporting rapid access to meaningful clinical insights and improved health outcomes.

Technology

Nanopath is revolutionizing the future of molecular diagnostics through its innovative surface plasmon resonance (SPR)-based technology platform. The company has developed a robust, rapid, and scalable SPR biosensor designed for real-world deployment, eliminating the need for nucleic acid amplification and significantly reducing time-to-result.

By combining rapid and sensitive detection with highly multiplexed capabilities, Nanopath’s technology can identify multiple biomarkers simultaneously, delivering comprehensive insights to clinicians and patients. Its cartridge-and-reader system provides lab-quality results in just 10–15 minutes at the point of care, enabling proactive, same-visit clinical decision-making. Backed by NIH and NSF support, Nanopath is advancing diagnostic innovation through scientific rigor, proprietary manufacturing capabilities, and a low-cost, user-friendly platform designed to improve healthcare accessibility.

Vision

Nanopath is focused on transforming women’s health diagnostics by addressing long-standing limitations in point-of-care testing. The company is working to establish a new standard of care by delivering immediately actionable results that empower both patients and healthcare providers. Through its innovative diagnostic platform, Nanopath aims to reimagine testing workflows by bringing comprehensive, lab-quality results directly to the point of patient care, enabling faster answers and more informed clinical decisions.

Starting with women’s health, Nanopath is developing an integrated suite of assays designed to improve the diagnosis and management of conditions such as urinary tract infections, human papillomavirus (HPV), vaginitis, and sexually transmitted infections. The company’s technology is designed to move beyond condition-specific testing by providing a more holistic approach to understanding patient health, with potential applications extending beyond women’s health.

Expanding Access to Actionable Women’s Health Diagnostics

Women’s health diagnostics have historically faced significant limitations, with many point-of-care testing approaches for pelvic and gynecologic infections remaining largely unchanged for decades. Nanopath is addressing this gap by creating diagnostic solutions designed specifically around the needs of patients and providers, enabling faster access to clinically meaningful information during a single healthcare visit.

The company’s platform is designed to simplify diagnostic workflows by bringing comprehensive, lab-quality results closer to the point of patient care. By reducing reliance on traditional laboratory processes and enabling rapid decision-making, Nanopath aims to help clinicians move from uncertainty to informed treatment decisions more efficiently.

Nanopath’s technology has broad potential across multiple areas of healthcare, beginning with women’s health applications. The company’s pipeline includes diagnostic solutions for conditions such as urinary tract infections, human papillomavirus (HPV), vaginitis, and sexually transmitted infections. Through an integrated suite of assays, Nanopath is working toward a future where diagnostic testing captures a more complete picture of patient health rather than addressing individual conditions through fragmented workflows.

The company’s interdisciplinary team brings together expertise across nanotechnology, assay development, engineering, and molecular diagnostics to advance its mission of improving human health. Founded on scientific innovation and supported by organizations including the National Institutes of Health (NIH) and National Science Foundation (NSF), Nanopath continues to translate advanced biosensing technologies into accessible diagnostic solutions designed for real-world clinical environments.

ALISON BURKLUND, PH.D. | CO-FOUNDER & CO-CEO

Alison Burklund, co-founder, is the co-CEO of Nanopath. Alison brings experience in the development of low-cost, rapid diagnostic systems, and a diverse background in entrepreneurship and technology translation. Alison is passionate about improving health and health access for underserved populations through commercialization of state-of-the-art technologies. Alison received her B.S. in Chemical and Biomolecular Engineering from Johns Hopkins University in 2015, her M.Eng. in Bioengineering from UC Berkeley in 2016, and her Ph.D. from Dartmouth in 2021, where she was a fellow in the prestigious Ph.D. Innovation Program.